Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

(2015) Tomas Kalincik et al.   ANNALS OF NEUROLOGY

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

(2012) David C. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Interferon   for secondary progressive multiple sclerosis: a systematic review

(2012) L. L. Mantia et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Increasing age at disability milestones among MS patients in the MSBase Registry

(2012) Ilya Kister et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis

(2012) M. Tutuncu et al.   Multiple Sclerosis Journal

Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity

(2011) Małgorzata Siger et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS

(2011) Douglas S. Goodin et al.   PLoS One

Relapses in multiple sclerosis are age- and time-dependent

(2008) H Tremlett et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY